Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 38

1.

Outcomes in CCG-2961, a children's oncology group phase 3 trial for untreated pediatric acute myeloid leukemia: a report from the children's oncology group.

Lange BJ, Smith FO, Feusner J, Barnard DR, Dinndorf P, Feig S, Heerema NA, Arndt C, Arceci RJ, Seibel N, Weiman M, Dusenbery K, Shannon K, Luna-Fineman S, Gerbing RB, Alonzo TA.

Blood. 2008 Feb 1;111(3):1044-53. Epub 2007 Nov 13.

2.

Gene transfer of cytidine deaminase protects myelopoiesis from cytidine analogs in an in vivo murine transplant model.

Rattmann I, Kleff V, Sorg UR, Bardenheuer W, Brueckner A, Hilger RA, Opalka B, Seeber S, Flasshove M, Moritz T.

Blood. 2006 Nov 1;108(9):2965-71. Epub 2006 Jul 11.

3.

Gemcitabine pharmacogenomics: cytidine deaminase and deoxycytidylate deaminase gene resequencing and functional genomics.

Gilbert JA, Salavaggione OE, Ji Y, Pelleymounter LL, Eckloff BW, Wieben ED, Ames MM, Weinshilboum RM.

Clin Cancer Res. 2006 Mar 15;12(6):1794-803.

4.

The human equilibrative nucleoside transporter 1 mediates in vitro cytarabine sensitivity in childhood acute myeloid leukaemia.

Hubeek I, Stam RW, Peters GJ, Broekhuizen R, Meijerink JP, van Wering ER, Gibson BE, Creutzig U, Zwaan CM, Cloos J, Kuik DJ, Pieters R, Kaspers GJ.

Br J Cancer. 2005 Dec 12;93(12):1388-94.

5.

Resistance to cytarabine and gemcitabine and in vitro selection of transduced cells after retroviral expression of cytidine deaminase in human hematopoietic progenitor cells.

Bardenheuer W, Lehmberg K, Rattmann I, Brueckner A, Schneider A, Sorg UR, Seeber S, Moritz T, Flasshove M.

Leukemia. 2005 Dec;19(12):2281-8.

PMID:
16304576
6.

Pilot study of idarubicin-based intensive-timing induction therapy for children with previously untreated acute myeloid leukemia: Children's Cancer Group Study 2941.

Lange BJ, Dinndorf P, Smith FO, Arndt C, Barnard D, Feig S, Feusner J, Seibel N, Weiman M, Aplenc R, Gerbing R, Alonzo TA.

J Clin Oncol. 2004 Jan 1;22(1):150-6.

PMID:
14701777
7.

Differential mRNA expression of Ara-C-metabolizing enzymes explains Ara-C sensitivity in MLL gene-rearranged infant acute lymphoblastic leukemia.

Stam RW, den Boer ML, Meijerink JP, Ebus ME, Peters GJ, Noordhuis P, Janka-Schaub GE, Armstrong SA, Korsmeyer SJ, Pieters R.

Blood. 2003 Feb 15;101(4):1270-6. Epub 2002 Oct 24.

8.

In vivo mechanisms of resistance to cytarabine in acute myeloid leukaemia.

Galmarini CM, Thomas X, Calvo F, Rousselot P, Rabilloud M, El Jaffari A, Cros E, Dumontet C.

Br J Haematol. 2002 Jun;117(4):860-8.

PMID:
12060121
9.

Nucleoside analogues: mechanisms of drug resistance and reversal strategies.

Galmarini CM, Mackey JR, Dumontet C.

Leukemia. 2001 Jun;15(6):875-90. Review.

PMID:
11417472
10.

Structural and functional analysis of the cytidine deaminase gene in patients with acute myeloid leukaemia.

Schröder JK, Kirch C, Seeber S, Schütte J.

Br J Haematol. 1998 Dec;103(4):1096-103.

PMID:
9886326
11.

Recombinant gene products of two natural variants of the human cytidine deaminase gene confer different deamination rates of cytarabine in vitro.

Kirch HC, Schröder J, Hoppe H, Esche H, Seeber S, Schütte J.

Exp Hematol. 1998 May;26(5):421-5.

PMID:
9590659
13.

Resistance to cytosine arabinoside by retrovirally mediated gene transfer of human cytidine deaminase into murine fibroblast and hematopoietic cells.

Momparler RL, Eliopoulos N, Bovenzi V, Létourneau S, Greenbaum M, Cournoyer D.

Cancer Gene Ther. 1996 Sep-Oct;3(5):331-8.

PMID:
8894252
14.

Transfection of murine fibroblast cells with human cytidine deaminase cDNA confers resistance to cytosine arabinoside.

Momparler RL, Laliberté J, Eliopoulos N, Beauséjour C, Cournoyer D.

Anticancer Drugs. 1996 May;7(3):266-74.

PMID:
8791999
15.

Cytidine deaminase. The 2.3 A crystal structure of an enzyme: transition-state analog complex.

Betts L, Xiang S, Short SA, Wolfenden R, Carter CW Jr.

J Mol Biol. 1994 Jan 14;235(2):635-56.

PMID:
8289286
16.

Improved prospects for long-term survival in adults with acute myelogenous leukemia.

Keating MJ, McCredie KB, Bodey GP, Smith TL, Gehan E, Freireich EJ.

JAMA. 1982 Nov 19;248(19):2481-6.

PMID:
6957624
17.

Cytosine arabinoside transport by human leukaemic cells.

Wiley JS, Jones SP, Sawyer WH.

Eur J Cancer Clin Oncol. 1983 Aug;19(8):1067-74.

PMID:
6684553
18.

Cytosine arabinoside (NSC-63878) therapy for acute leukemia in adults.

Bodey GP, Freireich EJ, Monto RW, Hewlett JS.

Cancer Chemother Rep. 1969 Feb;53(1):59-66. No abstract available.

PMID:
5772656
20.

Antitumor effect and mode of action of 1-beta-D-arabinofuranosylcytosine 5'-phosphate in leukemia L1210.

Schrecker AW, Goldin A.

Cancer Res. 1968 Apr;28(4):802-3. No abstract available.

Supplemental Content

Support Center